Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canopy GrowthFRA:11L -0.48%36 Debt-to-EBITDA is 8.66 as of Jun. 2026. GuruFocus rates FRA:11L with a GF Score™ of 36/100 and a GF Value™ of €0.61 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Canopy Growth ranks worse than 146842.73% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Canopy Growth's Debt-to-EBITDA or its related term are showing as below:
FRA:11L'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -30.96 Med: -1.29 Max: -0.28
Current: -1.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of Canopy Growth was -0.28. The lowest was -30.96. And the median was -1.29.
FRA:11L's Debt-to-EBITDA is ranked worse than 100% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs FRA:11L: -1.75
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Canopy Growth Debt-to-EBITDA Related Terms
Canopy Growth Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Canopy Growth (FRA:11L) has a Debt-to-EBITDA of 8.66 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Canopy Growth. According to the industry distribution chart, Canopy Growth ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Canopy Growth's Debt-to-EBITDA too high?
Canopy Growth's current Debt-to-EBITDA is 8.66. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Canopy Growth's value of 8.66 is 431.3% above this industry median. Based on the distribution chart, Canopy Growth ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Canopy Growth has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #999999 out of 681 companies for Debt-to-EBITDA. This places Canopy Growth in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Canopy Growth's value of 8.66 is 431.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current Debt-to-EBITDA of 8.66 is 431.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Canopy Growth. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Debt-to-EBITDA is 8.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (FRA:11L) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.61, compared to a current price of €0.87 — trading 42.4% above its estimated fair value. The current Debt-to-EBITDA is 8.66 and 431.3% above the Drug Manufacturers industry median of 1.63. Canopy Growth's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Canopy Growth (FRA:11L), the current Debt-to-EBITDA is 8.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (FRA:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.87 is trading 42.4% above its estimated GF Value™ of €0.61.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for FRA:11L:
Debt-to-EBITDA: 8.66
GF Value™: €0.61 vs. price of €0.87 (42.4% above fair value)
Industry Position: 431.3% above the Drug Manufacturers median (#999999 of 681)
No single metric tells the full story. See the FRA:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
36GF Score
Get the complete analysis for FRA:11L
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:11L has been successfully added to your 
